Plasma Fractionation Market Research Report Forecast to 2030

The Plasma Fractionation Market is expected to register a healthy CAGR of 9.1% during the forecast period. The creating use of immunoglobulins for various supportive regions and interest in plasma-deduced restorative things drive the market advancement driving market improvement.

Immunoglobulins are used as first-line treatment for various neurologic, immunologic, and hematologic conditions. To some degree as of late, the finding speed of various immunological diseases has extended in view of mechanical types of progress. The creation inherited assessment for portraying and diagnosing immunodeficiency will similarly extend the clinical necessity for immunoglobulins in view of the extended number of dissected patients. Moreover, the inescapability of unprecedented and safe framework diseases and an extension in immunology research by and large are further driving the advancement of this part. According to data circulated by the Public Spot for Advancing Translational Sciences in February 2022, there are about 7,000 to 10,000 unprecedented ailments impacting individuals, of which a few hundred have any treatment. Further, the rising number of captivating diseases is adding to the advancement of the immunoglobulin market area.

Market Segmentation

The Market segments of Plasma Fractionation, based on product type, include immunoglobulin, coagulation factor concentrates, albumin, protease inhibitors, and others.

The Plasma Fractionation Market based on Application is classified into immunology, neurology, hematology, critical care, pulmonology, rheumatology, hemato-oncology, and others. Based on an end-user the market is segmented into hospitals and clinics, clinical research laboratories, academic institutes, and others.

Regional Insights

The North American plasma fractionation market represented the biggest market share in 2022. This is because of the rising pervasiveness of different hereditary sicknesses, the developing geriatric populace, and expanding medical care use in the region. The high commonness of Alzheimer's illness and the viability of the plasma fractionation item in the treatment support the market development over the gauge period. Europe plasma fractionation market represents the second-biggest market share because of the rising predominance of immunodeficiency and draining issues in the region and expanding interests in these frameworks.

The Asia-Pacific plasma fractionation market is supposed to develop at a critical offer from 2023 to 2032. This is because of an expansion out in the open and confidential subsidizing for innovative work, great unofficial laws, expanded utilization of immunoglobulins, rising commonness of target illnesses with a maturing populace with blood-related sicknesses, and rising plasma-based therapy reception in the Asia-Pacific region.

The Rest of the World is fragmented into the Center East, Africa, and Latin America. plasma fractionation market in the previously mentioned regions is probably going to observe development because of the commonness of immune system illnesses in the regions. In addition, The Assembled Bedouin Emirates (UAE), Saudi Arabia, and South Africa are the 3 significant nations in the MEA.

Major Players

Key Companies in the market of Plasma Fractionation are CSL Behring (US), Grifols Therapeutics (Spain), Baxter International Inc (US), Hualan Bio (China), Mitsubishi Tanabe (Japan), Takeda Pharmaceutical (Japan), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), LFB Group (France), and Biotest AG (Germany).

Product Code: MRFR/HC/5928-CR

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1.1 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE
1.1.2 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION
1.1.3 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER
1.1.4 GLOBAL PLASMA FRACTIONATION MARKET, BY REGION

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 SCOPE OF THE STUDY
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 TOP DOWN & BOTTOM-UP APPROACH
3.6 FORECAST MODEL
3.7 LIST OF ASSUMPTIONS

4 MARKET DYNAMICS

4.1 DRIVERS
- 4.1.1 GROWING USE OF IMMUNOGLOBULINS FOR VARIOUS THERAPEUTIC AREA
- 4.1.2 DEMAND FOR PLASMA DERIVED MEDICINAL PRODUCTS DRIVES THE MARKET GROWTH
- 4.1.3 DRIVER IMPACT ANALYSIS
4.2 RESTRAINTS
- 4.2.1 EMERGENCE OF RECOMBINANT THERAPIES AS AN ALTERNATIVE TO PLASMA DERIVED MEDICINES RESTRAINTS THE MARKET GROWTH
- 4.2.2 RESTRAINT IMPACT ANALYSIS
4.3 OPPORTUNITIES
- 4.3.1 LAUNCH OF NEW TECHNOLOGIES BY KEY PLAYERS TO AUGMENT MARKET GROWTH

5 MARKET FACTOR ANALYSIS

5.1 SUPPLY CHAIN ANALYSIS
- 5.1.1 RAW APPLICATIONS
- 5.1.2 MANUFACTURES
- 5.1.3 DISTRIBUTION
- 5.1.4 END USER
5.2 PORTER'S FIVE FORCES MODEL
- 5.2.1 THREAT OF NEW ENTRANTS
- 5.2.2 BARGAINING POWER OF SUPPLIERS
- 5.2.3 THREAT OF SUBSTITUTES
- 5.2.4 BARGAINING POWER OF BUYERS
- 5.2.5 INTENSITY OF RIVALRY
5.3 MAJOR COLD CHAIN PRODUCTS/DEVICES IN THE PLASMA FRACTIONATION MARKET
5.4 IMPACT OF COVID-19 ON THE GLOBAL PLASMA FRACTIONATION MARKET
- 5.4.1 IMPACT ON SUPPLY CHAIN
- 5.4.2 IMPACT ON PRODUCTION
- 5.4.3 IMPACT ON REGIONS
- 5.4.4 IMPACT ON DEMAND-SUPPLY GAP ANALYSIS
- 5.4.5 IMPACT ON PRICING

6 GLOBAL PLASMA FRACTIONATION MARKET, BY PRODUCT TYPE

6.1 OVERVIEW
6.2 IMMUNOGLOBULIN
- 6.2.1 Intravenous Immunoglobulins
- 6.2.2 Subcutaneous Immunoglobulins
- 6.2.3 Others
6.3 COAGULATION FACTOR CONCENTRATES
- 6.3.1 Factor VIII
- 6.3.2 Factor IX
- 6.3.3 Von Willebrand Factor
- 6.3.4 Prothrombin Complex Concentrate
- 6.3.5 Fibrinogen Concentrates
- 6.3.6 Factor XIII
6.4 ALBUMIN
6.5 PROTEASE INHIBITORS
6.6 OTHERS

7 GLOBAL PLASMA FRACTIONATION MARKET, BY APPLICATION

7.1 OVERVIEW
7.2 IMMUNOLOGY
7.3 NEUROLOGY
7.4 HEMATOLOGY
7.5 CRITICAL CARE
7.6 PULMONOLOGY
7.7 RHEUMATOLOGY
7.8 HEMATO-ONCOLOGY
7.9 OTHERS

8 GLOBAL PLASMA FRACTIONATION MARKET, BY END USER

8.1 OVERVIEW
8.2 HOSPITALS & CLINICS
8.3 CLINICAL RESEARCH LABORATORIES
8.4 ACADEMIC INSTITUTES
8.5 OTHERS

9 GLOBAL PLASMA FRACTIONATION, BY REGION

9.1 OVERVIEW
9.2 NORTH AMERICA
- 9.2.1 US
- 9.2.2 CANADA
9.3 EUROPE
- 9.3.1 GERMANY
- 9.3.2 FRANCE
- 9.3.3 ITALY
- 9.3.4 SPAIN
- 9.3.5 UK
- 9.3.6 REST OF EUROPE
9.4 ASIA-PACIFIC
- 9.4.1 CHINA
- 9.4.2 JAPAN
- 9.4.3 INDIA
- 9.4.4 AUSTRALIA
- 9.4.5 SOUTH KOREA
- 9.4.6 REST OF ASIA PACIFIC
9.5 REST OF THE WORLD
- 9.5.1 LATIN AMERICA
- 9.5.2 MIDDLE EAST
- 9.5.3 AFRICA

10 COMPETITIVE LANDSCAPE

10.1 COMPETITIVE OVERVIEW
10.2 MAJOR GROWTH STRATEGY IN THE GLOBAL PLASMA FRACTIONATION MARKET
10.3 COMPETITIVE BENCHMARKING

11 COMPANY PROFILES

11.1 CSL BEHRING
- 11.1.1 COMPANY OVERVIEW
- 11.1.2 FINANCIAL OVERVIEW
- 11.1.3 PRODUCTS OFFERED
- 11.1.4 KEY DEVELOPMENTS
- 11.1.5 SWOT ANALYSIS
- 11.1.6 KEY STRATEGIES
11.2 GRIFOLS THERAPEUTICS
- 11.2.1 COMPANY OVERVIEW
- 11.2.2 FINANCIAL OVERVIEW
- 11.2.3 PRODUCTS OFFERED
- 11.2.4 KEY DEVELOPMENTS
- 11.2.5 SWOT ANALYSIS
- 11.2.6 KEY STRATEGIES
11.3 BAXTER INTERNATIONAL INC.
- 11.3.1 COMPANY OVERVIEW
- 11.3.2 FINANCIAL OVERVIEW
- 11.3.3 PRODUCTS OFFERED
- 11.3.4 KEY DEVELOPMENTS
- 11.3.5 SWOT ANALYSIS
- 11.3.6 KEY STRATEGIES
11.4 MITSUBISHI TANABE
- 11.4.1 COMPANY OVERVIEW
- 11.4.2 FINANCIAL OVERVIEW
- 11.4.3 PRODUCTS OFFERED
- 11.4.4 KEY DEVELOPMENTS
- 11.4.5 SWOT ANALYSIS
- 11.4.6 KEY STRATEGIES
11.5 TAKEDA PHARMACEUTICAL
- 11.5.1 COMPANY OVERVIEW
- 11.5.2 FINANCIAL OVERVIEW
- 11.5.3 PRODUCTS OFFERED
- 11.5.4 KEY DEVELOPMENTS
- 11.5.5 SWOT ANALYSIS
- 11.5.6 KEY STRATEGIES
11.6 OCTAPHARMA AG
- 11.6.1 COMPANY OVERVIEW
- 11.6.2 FINANCIAL OVERVIEW
- 11.6.3 PRODUCTS OFFERED
- 11.6.4 KEY DEVELOPMENTS
- 11.6.5 SWOT ANALYSIS
- 11.6.6 KEY STRATEGIES
11.7 HUALAN BIO
- 11.7.1 COMPANY OVERVIEW
- 11.7.2 FINANCIAL OVERVIEW
- 11.7.3 PRODUCTS OFFERED
- 11.7.4 KEY DEVELOPMENTS
11.8 KEDRION S.P.A
- 11.8.1 COMPANY OVERVIEW
- 11.8.2 FINANCIAL OVERVIEW
- 11.8.3 PRODUCTS OFFERED
- 11.8.4 KEY DEVELOPMENTS
11.9 LFB GROUP
- 11.9.1 COMPANY OVERVIEW
- 11.9.2 FINANCIAL OVERVIEW
- 11.9.3 PRODUCTS OFFERED
- 11.9.4 KEY DEVELOPMENTS
11.10 BIOTEST AG
- 11.10.1 COMPANY OVERVIEW
- 11.10.2 FINANCIAL OVERVIEW
- 11.10.3 PRODUCTS OFFERED
- 11.10.4 KEY DEVELOPMENTS
- 11.10.5 SWOT ANALYSIS
- 11.10.6 KEY STRATEGIES